Barclays set a €85.00 ($98.84) price objective on Bayer (FRA:BAYN) in a research report released on Thursday, September 26th, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other brokerages also recently issued reports on BAYN. Independent Research set a €65.00 ($75.58) price target on Bayer and gave the stock a sell rating in a research report on Wednesday, August 21st. JPMorgan Chase & Co. restated a neutral rating on shares of Bayer in a research report on Tuesday, August 20th. Deutsche Bank set a €70.00 ($81.40) target price on Bayer and gave the company a neutral rating in a research report on Friday, August 9th. Kepler Capital Markets set a €70.00 ($81.40) price target on Bayer and gave the company a neutral rating in a report on Thursday, June 27th. Finally, Bank of America set a €95.00 ($110.47) price target on Bayer and gave the company a buy rating in a report on Friday, September 13th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. Bayer has an average rating of Hold and an average target price of €79.90 ($92.91).
Shares of BAYN traded up €1.08 ($1.26) during mid-day trading on Thursday, reaching €65.22 ($75.84). The company had a trading volume of 2,789,121 shares. The stock has a 50 day moving average of €65.81 and a two-hundred day moving average of €60.47. Bayer has a 52-week low of €91.58 ($106.49) and a 52-week high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.